期刊文献+

曲美他嗪治疗糖尿病性心肌病的临床疗效观察

原文传递
导出
摘要 目的糖尿病性心肌病(DCM)患者常规治疗基础上加用曲美他嗪,观察其临床疗效.方法:纳入我院48例DCM患者,分为治疗组和对照组.治疗12周,对比血浆中脑钠素(BNP) 和N一末端脑钠素前体(Nt-proBNP) 浓度,通过心脏彩超评价心脏收缩功能的改善情况.结果:治疗后12周,两组患者的疗效间差异有统计学意义( p〈0.01);两组患者的血浆中脑钠素(BNP) 和N-末端脑钠素前体(Nt-proBNP) 浓度;左室舒张末期内径、左室射血分数、左室短轴缩短率间差异均有统计学意义(p〈0.01).结论:曲美他嗪能够改善糖尿病性心肌病的心功能,是一种安全有效的新方法.
出处 《中医学报》 CAS 2014年第B12期317-318,共2页 Acta Chinese Medicine
  • 相关文献

参考文献4

  • 1DiNapoli P,Tacacrdi A A,Barsutti A.Zong term eardiop rotective action oftrimetazidinl and potential ehect on the imflammatory process in patients with ischaemiedilated eardiomy opatuy[J].Heart.2005,91:161.
  • 2Aussedat J, Ray A, Kay L, et al. Improvement of longterm preservation of isolatedheart ; beneficial effect of anti-is chemicagent trimetazidine[J].CardiovascularPharamcol,1993,21:128.
  • 3曲美他嗪对慢性心力衰竭血浆N2 端脑钠素前体、脑钠素的影响赵士超,曹林生,J Clin Cardi0l (China) , 0ct 2004 ,VOL 20 , NO 10:622-623.
  • 4吴绮楠,肖谦,吴平,李龙英,高原.曲美他嗪对2型糖尿病大鼠心肌细胞凋亡的影响[J].第三军医大学学报,2007,29(19):1866-1868. 被引量:7

二级参考文献11

  • 1张晓燕,陈丽红,管又飞.PPAR家族及其与代谢综合征的关系[J].生理科学进展,2005,36(1):6-12. 被引量:39
  • 2周迎生,高妍,李斌,刘冬戈,迟家敏,王抒,黎健.高脂喂养联合链脲佐菌素注射的糖尿病大鼠模型特征[J].中国实验动物学报,2005,13(3):154-158. 被引量:122
  • 3张学亮,冯晓丽,徐静,郑宏庭,陈卫.曲美他嗪对2型糖尿病患者血乳酸水平的影响[J].第三军医大学学报,2005,27(24):2478-2479. 被引量:1
  • 4Young M E, Laws F A, Goodwin G W, et al. Reactivation of peroxisome proliferator-activated receptor alpha is associated with contractile dysfunction in hypertrophied rat heart [ J ]. J Biol Chem, 2001,276 ( 48 ) :44390 - 44395.
  • 5Finck B N, Han X, Courtois M, et al. A critical role for PPARalpha- mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content [ J ]. Proc Natl Acad Sci U S A, 2003, 100(3) :1226- 1231.
  • 6Rosano G M, Vitale C, Sposato B, et al. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study[ J ]. Cardiovasc Diabetol, 2003, 28(2) : 16.
  • 7Tabbi-Anneni I, Helies-Toussaint C, Morin D, et al. Prevention of heart failure in rats by trimetazidine treatment : a consequence of accelerated phospholipid turnover? [ J]. J Pharmacol Exp Ther, 2003, 304 (3) : 1003 -1009.
  • 8Fang Z Y, Prins J B, Marwick T H. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications [ J ]. Endocr Rev, 2004, 25(4) : 543 -567.
  • 9Lefebvre P, Chinetti G, Fruchart J C, et al. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis[ J ]. J Clin Invest, 2006, 116(3) : 571 -550.
  • 10Matsuzawa Y. The metabolic syndrome and adipocytokines[ J ]. FEBS Lett, 2006, 580(12): 2917-2921.

共引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部